Tempus provides sequencing services and analyzes somatic and germline molecular data along with therapeutic data to empower physicians to make data-driven decisions.Contact us to learn more
A new approach to next-generation sequencing.
Tempus gives doctors access to a variety of sequencing capabilities, all with full transcriptome and tumor/normal match. We partner with physicians and hospitals to augment a hospital's current offering by providing access to genomic sequencing with cutting-edge analytics and an interactive machine learning platform that also leverages data from biological models, proteomics and single cell genomics.Contact us to order a sequencing test
We've built a state-of-the-art lab to bring data science and technology into clinical care. The CLIA-certified Tempus Lab is a highly robotic laboratory optimized for high-throughput clinical next-generation sequencing with a current capacity of over 50,000 patients annually.
All sequencing includes RNA-seq capture and germline. Sequencing is completed within ~two weeks to three weeks of receiving patient samples.
Once you decide you would like to work with Tempus, contact us at email@example.com and we will send you appropriate manuals, forms and specimen collection kits based on your specific needs and requirements.
How do I order a Tempus test?
A test can be ordered by faxing a completed requisition form to us at 708.575.1789.
What type of sequencing does Tempus perform?
Our labs sequence both DNA and RNA from tumor samples as well as matched DNA from normal samples. Sequencing options include a targeted panel of ~600 genes (at 500x coverage), an onco-seq panel of ~1700 genes (at 500x coverage), whole exome (at 150x coverage) and whole genome (at 30x coverage).
Is the Tempus Lab CLIA-certified and CAP-accredited?
Yes, the lab is CLIA-certified and CAP-accredited.
What are Tempus' specimen requirements and how are they obtained?
Tempus requires your patient's tumor and blood or saliva specimens for DNA and RNA extraction and amplification. Tissue specimen handling and preparation procedures should meet our requirements, which are available here. Tempus handles obtaining the tumor specimen.
What sequencing analysis is performed?
Somatic sequencing using formalin-fixed or fresh-frozen samples to identify genomic aberrations in cancer malignancies. All sequencing data will be available for analysis, and all potentially relevant therapies are reported and prioritized based on the strength of the clinical evidence that establishes the association between a given genomic alteration and a relevant therapeutic option.
RNA sequencing using tumor samples to analyze actionable genomic aberrations (e.g. gene fusions), gene expression analysis, rare and novel transcript discovery, and splice variant detection.
What results of the genomic analysis are included in the clinical report?
Tempus reports on all relevant therapeutic indications for detected somatic or gene expression alterations for which there is clinical evidence linking a given alteration to any FDA approved therapy in the cancer under study, or another cancer, and for alterations associated with a known or suspected contraindication to a given therapy. The first page summarizes the most relevant therapies with potential benefit and potential lack of benefit. Relevant therapies are prioritized based on the strength of the clinical evidence that establishes the association between a given genomic alteration and a relevant therapeutic option. The report cites all of the references for the clinical evidence that establishes the association between each genomic alteration and its matching therapy and additionally provides a complete bibliography of published research relevant to the targeted biomarkers and therapies. The clinical trials section matches your patient to eligible biomarker-based clinical trials.
How do we know our FFPE RNA calls are accurate relative to fresh tissue?
Tempus uses capture RNA-seq to assess gene rearrangements and RNA expression levels from clinical FFPE tissue samples. This method is based on techniques published by Tempus scientific advisor Arul Chinnaiyan: "Through validation against gold-standard poly(A) and Ribo-Zero libraries from intact RNA, we show that capture RNA-seq provides accurate and unbiased estimates of RNA abundance, uniform transcript coverage, and broad dynamic range. Unlike poly(A) selection and Ribo-Zero depletion, capture libraries retain these qualities regardless of RNA quality and provide excellent data from clinical specimens including formalin-fixed paraffin-embedded (FFPE) blocks."
How do I obtain the results?
A PDF of the summary section of the report will be emailed to you. In addition, when your first Tempus report is complete, you will receive an email with your unique login information. Once the report is complete, you will be able to login to access your patient’s detailed report, including both the clinical and research sections.
What is Tempus' turnaround time for test results?
Tempus sequencing results are returned within approximately two to three weeks of receipt of samples (both blood and tissue). Sequencing will not begin until all required specimens are received.
Does Tempus offer research services?
Yes, we work with many academic institutions and principal investigators on research projects pertaining to genomic sequencing of cancer patients. Please email firstname.lastname@example.org to get started.
Who do I contact if I have additional questions or need software support?
How will knowing more about my genomic alterations help determine a treatment plan?
Knowing the alterations that are driving your cancer may help to identify targeted FDA-approved and clinical trial therapies that in some cases have been proven to be more effective than organ- and tissue-specific treatments.
How do you order the test and what information needs to be provided?
Your doctor will need to order the test directly from Tempus by completing a simple requisition form. We will coordinate the collection of specimen samples (blood or saliva, as necessary) and will request the tumor sample from your hospital's pathology department.
How long does it take to get results from the test?
From the time Tempus receives the necessary specimen samples, it typically takes approximately two to three weeks to sequence and generate your report. The report will be delivered to your physician, who will contact you when the results are received.
Is the test covered by my health insurance or by Medicare?
We will work with your insurance company to submit for reimbursement. A comprehensive patient-assistance program is also available. Our patient financial assistance form is available here.
How does Tempus obtain my tumor sample for testing?
We will work with your hospital’s pathology department to obtain your tissue sample. Your tumor sample will be sent to our secure sequencing lab in Chicago.
What is included in the final report?
We generate a comprehensive report that will present your tumor biology, potential targeted therapies and your patient history. The report will also highlight recruiting clinical trials, if available, that fit your profile. We also provide other insights for deeper exploration of available options.
How do I get a copy of my test results?
The report will be sent to your physician to share with you.
Is the Tempus test right for me?
Our services explore options for patients with metastatic, refractory and recurrent cancer. Eligible patients include those with cancer of unknown origin; rare or uncommon solid tumors with limited treatment options; solid tumors not responding to standard of care; recurrent or metastatic cancer, or an interest in enrolling in clinical trials. It's up to your doctor to decide if genetic sequencing can help in your cancer treatment.
How is your sequencing better than others?
Our comprehensive approach checks hundreds of genes for alterations by testing both the tumor tissue DNA and the normal tissue DNA along with testing the RNA. By testing all three together, we improve the detection of tumor-specific alterations and take a deep look into your tumor's biology.